Small animal irradiation is crucial to the investigation of radiobiological mechanisms. The paradigm of clinical radiotherapy is trending to high-precision, stereotactic treatment. However, translating this scheme to small animal irradiation is challenging due to the lack of high-quality image guidance.
Studies of the normal functions and diseases of the prostate request in vivo models that maintain the tissue architecture and the multiple-cell type compartments of human origin in order to recapitulate reliably the interactions of different cell types.
An accurate assessment of out-of-field dose is necessary to estimate the risk of second cancer after radiotherapy and the damage to the organs at risk surrounding the planning target volume. Although treatment planning systems (TPSs) calculate dose distributions outside the treatment field, little is known about the accuracy of these calculations.
We performed an audit to evaluate the impact of the COVID-19 pandemic-related delay in the diagnosis of major cancers at a Pathology Unit of a Secondary Care Hospital Network in Italy. A comparison was made among the number of first cellular pathological diagnoses of malignancy made from the 11th to the 20th week of the […]
Bladder cancer is an increasingly common malignancy, and muscle invasive bladder cancer is associated with particularly high rates of morbidity and mortality. The morphologic and molecular diversity of bladder cancer poses significant challenges in elucidating the invasion mechanisms responsible for disease progression.
Forward Momentum brings together healthcare, research, and advocacy organizations Initial projects focus on increasing diversity in COVID-19 research and developing digital resources to support the overall health of men with prostate cancer San Francisco, CA (UroToday.com) — BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences announced the launch of Forward Momentum, a cross-sector coalition working on innovative projects to increase diversity in research and develop new digital resources for men with prostate cancer.
We report efficacy and safety with extended follow-up, and exploratory biomarker analyses from the phase II CheckMate 275 trial to identify biomarkers of response to nivolumab in platinum-resistant metastatic or unresectable urothelial carcinoma (mUC). Patients received nivolumab 3 mg/kg Q2W until disease progression, unacceptable toxicity, or other protocol-defined reasons. The primary endpoint was ORR per […]
June 26, 2020, marked the 20th anniversary of the publication of the first working draft from the Human Genome Project. At a special White House event to commemorate the results of this 10-year public effort (it was really more like 50 years since the discovery of DNA, but I digress), then-President Bill Clinton called the project “the […]
(UroToday.com) Upper tract urothelial carcinoma tumors have distinct genomic profiles that distinctly differentiate them from bladder cancer tumors. In the presented study, the authors characterized the prevalence of actionable genomic alterations and evidence supporting susceptibility to targeted therapies. In addition, they evaluated the prevalence of DNA damage response alterations associated with response to platinum-based chemotherapy […]
(UroToday.com) Patients who were treated with enzalutamide have shown increased expression of PD-L1 in circulating dendritic cells. Patients with greater PD-L1 expression were found to have worse response rates to enzalutamide treatment.1 There is a phase 2 single-institution study that assessed pembrolizumab + enzalutamide in patients whose disease progressed after enzalutamide (n=28)(2). In these patients, […]
